Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)

Summary

The National Institutes of Health (NIH) is soliciting applications under the Blueprint MedTech Translator program (PAR-25-383), using a UG3/UH3 cooperative agreement mechanism. This program supports the translation of medical devices and neurotechnology from early-stage development toward clinical application, with clinical trials designated as optional. The opportunity is a federal grant/cooperative agreement posted on Grants.gov and remains open for an extended multi-year window through January 2028.

How they evaluate

Risks & flags

• Extremely long open window (nearly 3 years) suggests rolling submission cycles — applicants should verify specific submission due dates within the FOA, as individual due dates may be more restrictive than the master close date
• Minimal scope detail provided in the synopsis; full Program Announcement (PAR-25-383) must be reviewed for complete requirements, eligibility, and evaluation criteria